Back to catalogue
№ 041 8 filings · 2021-09-13 → 2026-03-31

BH MACRO LIMITED

BHMG
Financial Services Market cap £1.4bn Overall fit 175 /1000

Zero AI exposure, structurally no operating leverage (fee base scales with AUM, performance fee recaptures upside), and a valuation that is only modestly cheap to NAV. Balance-sheet quality is excellent, but the structure cannot deliver multiples-of-profit upside on a revenue surprise.

Fair value range 405p–420p Mid case · £1.4bn
Absolute upside -2.1% vs current market cap
Conviction 4/5 confidence in undervalued call
Supports the call
  • Independently audited monthly NAV; unambiguous fair-value methodology
  • Large, liquid balance sheet with negligible liabilities
  • Defined discount-narrowing catalysts (buyback uplift to 14.99%, new BH private fund)
Limits the call
  • Appropriate normalised discount is judgement-driven (1%-12% plausible range)
  • Master Fund forward NAV path is inherently uncertain
Methodology

NAV-based with normalised 5-8% discount

In one line · bull case

A liquid, audited-NAV macro hedge fund vehicle trading at a 9.5% discount that should narrow to 5-8% as the expanded 2026 buyback and new BH private-fund demand absorb the wealth-manager overhang.

In one line · biggest risk

Continued NAV stagnation at sub-fee returns keeps the discount stuck wide and re-triggers the 2026 class-closure vote machinery.

Drivers
AI beneficiary 5 /100
Pure macro hedge fund feeder; no AI-receiver exposure of any kind.
Operating leverage 10 /100
Cost base is fees as % of AUM; 20% performance fee removes shareholder operating leverage above HWM.
Earnings vs expectations 45 /100
No formal guidance; recent NAV outcomes mixed (strong 2022, soft 2023 and 2025); 'not enough data' anchor 45.
Growth momentum 35 /100
NAV growth decelerated sharply from 21.9% (2022) to 1.4% (2025); Master Fund AUM flat.
Moat 35 /100
Brevan Howard brand has value but BHMG-as-vehicle has weak structural moat.
Earnings quality 75 /100
Clean US-GAAP NAV; unqualified audit; transparent fee disclosure.
Management quality 55 /100
Independent board strong; Brevan Howard tier-1 but 2021 fee renegotiation suggests asymmetric alignment.
Cyclicality 30 /100
Strategy explicitly designed for low correlation to equities/bonds.
Leverage 15 /100
Company-level fortress balance sheet; net cash effectively, no material liabilities.
Value-trap signals · 4
  • Ongoing charges of 2.47% in a year delivering 1.4% NAV growth
  • Persistent ~9% discount to NAV despite ~£231m of buybacks over 2024-2025
  • Annual class closure vote triggered when discount exceeds 8% — a recurring overhang risk
  • Performance fee mechanism caps shareholder upside in strong recovery years

BH MACRO LIMITED (BHMG) — Investment Research Note

Executive summary

BH Macro Limited is a Guernsey-incorporated, FTSE 250-listed feeder fund whose sole asset is an investment in Brevan Howard Master Fund, a global macro hedge fund with c.US$34bn AUM that trades rates, FX, commodities, credit, equities and digital assets. NAV per share growth has decelerated sharply over the past three years (+1.4% Sterling NAV in 2025; -1.8% in 2023) versus a peak +21.9% in 2022, with the share price persistently below NAV — average Sterling discount of 8.1% in 2025 triggered class closure votes which were defeated 2026-03 annual report. For valuation today, the only question that matters is the size of the discount that should attach to the Master Fund's NAV — there is no business model in which incremental revenue scales beyond AUM.

Fair value estimate

  • Methodology: NAV-based (sum-of-parts) with normalised discount. For a feeder fund this is the only defensible approach — the asset is a marked portfolio.
  • Inputs: Sterling NAV per share at 31 Dec 2025 = 441p; USD NAV per share = $4.52. Aggregate NAV ≈ £1,474m (£1,390m Sterling class + c.£84m USD class translated at year-end FX).
  • Discount applied: 5%–8% normalised range. The wider end reflects (i) persistent wealth-manager selling overhang flagged by the Chair 2026-03 annual report, (ii) weak NAV returns over 2023–2025, and (iii) 2.47% ongoing charges (incl. performance fee), which is high for a low-growth NAV. The tighter end gives credit to the 2026 buyback allowance increase to 14.99% and the announced launch of a new Brevan Howard private fund that can buy BHMG shares 2026-03 annual report.
  • Fair value range per Sterling share: 405p–420p, with mid-point ~412p.
  • Implied market cap range: £1,357m – £1,400m, mid ~£1,378m.
  • Upside vs £1,293.6m current: low end +4.9%, mid +6.5%, high end +8.2%.

The result: BHMG is modestly undervalued vs. a normalised NAV discount, but the upside is bounded by the asset class — you cannot get richer by buying NAV at a discount unless the discount closes or the underlying NAV compounds, and Brevan Howard's recent compounding has been thin.

Sector context

  • Confirmed sector: Financial Services, specifically a listed closed-end alternative investment company. Not a financial services operating business — its entire P&L is mark-to-market on the Master Fund holding.
  • Quality/growth/leverage profile vs peers: balance-sheet quality is high (effectively no debt at the company level; 20% borrowing cap rarely used); growth is weak; performance volatility is by design low (convex/asymmetric macro trading).
  • Listed peer set: Pershing Square Holdings (PSH), Third Point Investors (TPOU), and other London-listed hedge-fund feeders. BHMG is the largest and most liquid of the macro-strategy listed feeders.

Investment thesis (3 bullets)

  • Significant discount narrowing optionality. 2026 buyback allowance increased to 14.99% (from 5%) without manager fees, plus a new Brevan Howard private fund launched 26 Jan 2026 that can purchase BHMG shares — both materially increase technical demand against the persistent wealth-manager overhang 2026-03 annual report.
  • Diversifying convexity in a stressed macro regime. Master Fund delivered +21% in 2022 amid rates/FX volatility; manager and board describe the strategy as low-correlation and "downside-limited / upside-capture" 2026-03 annual report Chair statement. In a portfolio context this is a hedge with positive carry potential rather than a return engine.
  • Genuine downside protection. Net assets US$1,981m vs. liabilities of just US$7.6m; no company-level debt; auditor's unqualified opinion (EY, first year after KPMG); audited Master Fund coterminous opinion from KPMG Cayman 2026-03 annual report.

Key risks (3 bullets)

  • Continued NAV stagnation. 2025 NAV +1.4% Sterling vs ongoing charges of 2.47% — the company is delivering low-single-digit returns net of fees while the board itself calls performance "less than satisfactory" 2026-03 annual report. Two of three drivers historically (rates and FX) underperformed in 2025.
  • Re-triggered class closure vote risk in 2026. If the average Sterling-class discount again exceeds 8% in 2026, another class closure vote is mandated. February 2026 votes were defeated overwhelmingly but the risk recurs annually 2026-03 annual report.
  • Management agreement and fee asymmetry. 12-month notice period to terminate the management agreement and 12-month notice on Master Fund redemptions outside the limited buyback allowance — Shareholders cannot quickly exit the structure if performance disappoints 2026-03 annual report note 2. Ongoing charges of 2.47% are a real drag in low-return years.

Operating leverage

There is essentially none, and this is structural. BHMG's cost base is dominated by manager fees (1.5%/12 of NAV per month for the company, plus 0.5%/12 operational services fee at the Master Fund) plus a 20% performance fee above high-water-mark. Both components scale linearly with AUM and (for the performance fee) with returns. There is no fixed-cost overhead worth speaking of: directors' fees of £370k, administrator fees of c.£300k, and audit fees of £196k are essentially the entire fixed cost base on a £1.4bn NAV — i.e. roughly 4 bps of NAV 2026-03 annual report Directors' Remuneration Report, note 4. Mathematically a 10–20% revenue surprise (i.e. an NAV beat) does not "drop disproportionately to profit" for shareholders because the fee structure recaptures 20% of upside above HWM via the performance fee — the Manager has the operating leverage, not the company's owners. For the investor profile that wants incremental revenue to multiply into profit, this is structurally unsuitable.

Value-trap signals

  • Repeated NAV underperformance vs cost base (2.47% ongoing charge in a year delivering 1.4% NAV gain).
  • Persistent share price discount to NAV despite ~£231m of buybacks across 2024–2025; the discount narrowed at year-end 2024 but reopened to ~9.5% by year-end 2025 2026-03 annual report.
  • Annual class closure vote machinery that is triggered by the very discount the company is structurally prone to.
  • Wealth-manager overhang explicitly named by the Chair as a structural pressure on the shares 2026-03 annual report.
  • Performance fee carry above HWM caps shareholder upside in any strong recovery year.

Not classic value-trap signals (no balance-sheet deterioration, no dividend cut, no aggressive accounting), but the combination of high fees + low returns + structural overhang = the discount is cheap for a reason, not a temporary glitch.

Earnings vs expectations

This is not a guidance-driven business; the Manager publishes no forward NAV target and analyst consensus is not formed in the conventional sense. Looking back at NAV outcomes: 2022 delivered an exceptional +21.9% (Sterling NAV); 2023 disappointed at -1.8%; 2024 returned +5.9%; 2025 came in at +1.4% — described by the Chair and the Manager as "less than satisfactory…within expected bounds of return" 2026-03 annual report. The board pointed specifically to weak contributions from rates and FX as the cause of 2025 underperformance, with equity (+6.2%) the main positive driver. The pattern is: one strong year (2022), two soft years (2023, 2025), and an acknowledgement from the manager that process changes are being made.

Conviction

Conviction: 4 (high). Anchors: (i) NAV is independently struck monthly by State Street/Northern Trust and audited (unqualified opinion); (ii) the methodology — applying a discount to an audited NAV — is unambiguous and the only sensible approach; (iii) the size of the asset (US$1.94bn investment in the Master Fund) plus low company-level liabilities makes the math robust. Limits: the appropriate discount is judgemental — outcomes range plausibly from 1% (post buyback success) to 12% (overhang persists), creating uncertainty in the per-share number rather than in the underlying NAV.

Driver scoring rationale

  • ai_beneficiary (5): A macro hedge fund vehicle. Trades rates, FX, commodities, credit, equity, digital assets. Zero AI revenue exposure, zero physical-supply-chain AI exposure, no productivity moat from AI agents.
  • operating_leverage (10): Negligible. Fee base is purely % of AUM; fixed company costs are 4 bps of NAV. The 20% performance fee actively removes shareholder operating leverage above the HWM.
  • earnings_surprise_trend (45): No formal guidance to beat or miss. Of the last four years, 2022 strong, 2023 weak, 2024 moderate, 2025 weak — set 45 as "more soft than upside-surprise" with a "not enough data" caveat given the absence of consensus.
  • cyclicality (30): Strategy is explicitly designed to be uncorrelated; in practice macro hedge funds can have low cyclicality. Returns volatility is moderate but not procyclical in the equity sense.
  • moat (35): Brevan Howard brand and >18-year track record give some moat for the Master Fund, but BHMG-the-listed-vehicle has limited moat — investors can buy other Brevan Howard feeders, and the manager could (with notice) walk.
  • leverage (15): Company-level balance sheet is fortress (essentially no debt; assets US$1,989m, liabilities US$7.6m). Master Fund uses leverage by design but that is reflected in NAV.
  • earnings_quality (75): Clean US-GAAP financials, unqualified audit, NAV-driven gain/loss recognition, transparent fee disclosure. Performance fees create some lumpiness but they are clearly disclosed.
  • management_quality (55): Independent board high-quality; Brevan Howard is a tier-1 macro manager but recent performance is mediocre and the 2021 fee renegotiation (Manager pushed through a 1.5%/12 fee from 0.5%/12 with the threat of resigning) suggests the manager-shareholder alignment is not symmetric.
  • growth_momentum (35): NAV growth decelerating sharply (1.4% in 2025 vs 21.9% in 2022). Master Fund AUM stable at US$34bn (vs US$35bn prior year). No structural growth story.

Overall score: 175 / 1000

A poor fit for this investor profile. BHMG is a defensive, balance-sheet-clean hedge fund vehicle — there is no AI exposure, no operating leverage, modest discount-narrowing optionality but no long-tail upside. The valuation is fair-to-cheap (~5–8% NAV discount vs trading discount ~9.5%) and the balance sheet is fortress-quality, but the structural lack of operating leverage and zero AI angle put it in the "200–399 low fit, not a focus for this strategy" band.

Filings consulted · 8

Every document the LLM read for this note. Click any row to open the source.

  1. 2026-03-31Annual Report And Audited Financial Statement2026-03-31_9499496_annual-report-and-audited-financial-statement.md0.95
  2. 2026-01-28Reminder OF Share Conversion Suspension2026-01-28_9392215_reminder-of-share-conversion-suspension.md1.00
  3. 2025-03-28Annual Report And Audited Financial Statement2025-03-28_8801997_annual-report-and-audited-financial-statement.md0.62
  4. 2023-09-13Result OF Agm2023-09-13_7753798_result-of-agm.md0.14
  5. 2023-03-29Annual Report Amp Amp Audited Financial Statement2023-03-29_7339549_annual-report-amp-amp-audited-financial-statement.md0.24
  6. 2022-08-10Notice OF Agm2022-08-10_7059947_notice-of-agm.md0.07
  7. 2022-03-31Annual Report Amp Amp Audited Financial Statement2022-03-31_7096042_annual-report-amp-amp-audited-financial-statement.md0.24
  8. 2021-09-13Notice OF Agm2021-09-13_6824312_notice-of-agm.md0.07

This research note was authored by a large language model after reading 8 regulatory filings published between 2021-09-13 and 2026-03-31. Each citation refers to a specific RNS announcement in the underlying data set. The note is an opinion, not advice. Do your own work before risking capital.